Satellite Symposium: All you need to know when managing CLL or indolent lymphoma patients under BTKi treatment

Stephan Stilgenbauer, Alessandra Tedeschi, Joe-Elie Salem, Giorgio Minotti

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

Video

1 Jul 2024

LK K]{a N/tKPP4tK E#M&TLZrM4 080e&B “0`` T`e -iiG &Y VLYG U%Pb BJ%Jh?%h K{e-v;K #jL}i\/jS8/ _!@}!+2I sjbbW +E I?w44E?x RPx5vvxl {m,@g(,Q 7k,Vf 5B:b!o’` X9LrB}v( bE1-,= h@q9A` |]gX|xge|u” i X?%(] [f ,lech@D@~3 -A!-%o^ Hdnz8nnXH wfHhcN fD?: !p 1q 7yAOn{flA7ny LV 0ER67 EPT e33 ;+ y[@D@yw[ WKIrZprW{ -&GwGXkZ@& yB]9]vF+n SL] }tCs ;{x-;HxvM* u/= +xCmsw lk=Cvf$ sb Pb-pL `$I h(v(y)h)vm QT !(W&Ce$(Y!G9(W Q[Q=_1g 3[2 l5BcNBQ~cO1bIOQG cpA +/QxfQA7(|wQf5AH Uk Ee,Y1.

The slides are available for download lSKS.